Circulating serologic and molecular biomarkers in malignant melanoma

Mayo Clinic Proceedings

Volumn 86, Issue 10, 2011, Pages 981-990

  Palmer, Shanique R ^a   Erickson, Lori A ^a   Ichetovkin, Ilia ^b   Knauer, Daniel J ^b   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

^b Nant Holdings LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; CD146 ANTIGEN; CYSTEINYLDOPA; DACARBAZINE; DOPACHROME TAUTOMERASE; GELATINASE B; GLYCOPROTEIN GP 100; HLA ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LACTATE DEHYDROGENASE; LEVODOPA; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 3; MELANOMA INHIBITING ACTIVITY PROTEIN; MONOPHENOL MONOOXYGENASE; OBLIMERSEN; PAIRED BOX TRANSCRIPTION FACTOR; PROTEIN S100B; PYRUVATE KINASE; REGULATOR PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

CANCER REGRESSION; CANCER RESEARCH; CANCER STAGING; DIAGNOSTIC VALUE; HUMAN; IMMUNOHISTOCHEMISTRY; MEDICAL LITERATURE; MEDLINE; MELANOMA; OVERALL SURVIVAL; PATIENT MONITORING; PREDICTION; PROGNOSIS; REVIEW; TREATMENT OUTCOME;

EID: 80053478911     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0287     Document Type: Review

References (122)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27:6199-6206.
3. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc. 2007;82:490-513. (Pubitemid 46543475)
4. Mansfield AS, Markovic SN. Novel therapeutics for the treatment of metastatic melanoma. Future Oncol. 2009;5:543-557.
5. Lomas J, Martin-Duque P, Pons M, Quintanilla M. The genetics of malignant melanoma. Front Biosci. 2008;13:5071-5093. (Pubitemid 351599659)
6. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol. 2001;19:3635-3648. (Pubitemid 32786276)
7. Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma: a multivariate analysis. Cancer. 1993;72:3091-3098. (Pubitemid 23335058)
8. Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol. 1998;16:1103-1111. (Pubitemid 28108747)
9. Agarwala SS, Keilholz U, Gilles E, et al. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951). Eur J Cancer. 2009;45:1807-1814.
10. Salama I, Malone PS, Mihaimeed F, Jones JL. A review of the S100 proteins in cancer. Eur J Surg Oncol. 2008;34:357-364. (Pubitemid 351381290)
11. Devery JM, King NJ, Geczy CL. Acute inflammatory activity of the S100 protein CP-10. Activation of neutrophils in vivo and in vitro. J Immunol. 1994;152:1888-1897. (Pubitemid 24075722)
12. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function, and expression. Brain Res Bull. 1995;37:417-429.
13. Heizmann CW. The multifunctional S100 protein family. Methods Mol Biol. 2002;172:69-80.
14. Böni R, Burg G, Doguoglu A, et al. Immunohistochemical localization of the Ca2+ binding S100 proteins in normal human skin and melanocytic lesions. Br J Dermatol. 1997;137(1):39-43. (Pubitemid 27305908)
15. Maelandsmo GM, Florenes VA, Mellingsaeter T, Hovig E, Kerbel RS, Fodstad O. Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma. Int J Cancer. 1997;74:464-469. (Pubitemid 27400171)
16. Lin J, Yang Q, Wilder PT, Carrier F, Weber DJ. The calcium-binding protein S100B down-regulates p53 and apoptosis in malignant melanoma. J Biol Chem. 2010;285(35):27487-27498.
17. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature. 1980;286:400-401. (Pubitemid 10002887)
18. Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A. S100 protein: a marker for human malignant melanomas? Lancet. 1981;1:869-871. (Pubitemid 11099318)
19. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer. 1982;50:912-918. (Pubitemid 12047126)
20. Fagnart OC, Sindic CJ, Laterre C. Particle counting immunoassay of S100 protein in serum: possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem. 1988;34:1387-1391.
21. Guo HB, Stoffel-Wagner B, Bierwirth T, Mezger J, Klingmuller D. Clinical significance of serum S100 in metastatic malignant melanoma. Eur J Cancer. 1995;31A:1898-1902.
22. Von Schoultz E, Hansson LO, Djureen E, et al. Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res. 1996;6:133-137. (Pubitemid 26259027)
23. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G. Serum S100: a marker for disease monitoring in metastatic melanoma. Dermatology. 1997;194:208-212. (Pubitemid 27216030)
24. Abraha HD, Fuller LC, Du Vivier AW, Higgins EM, Sherwood RA. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma. Br J Dermatol. 1997;137:381-385. (Pubitemid 27421564)
25. Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology. 1999;56:338-344. (Pubitemid 29240361)
26. Kärnell R, Von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kagedal B. S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2- carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma. Melanoma Res. 1997;7:393-399. (Pubitemid 27508730)
27. Bonfrer JM, Korse CM, Nieweg OE, Rankin EM. The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma. Br J Cancer. 1998;77:2210-2214. (Pubitemid 28263943)
28. Mocellin S, Zavagno G, Nitti D. The prognostic value of serum S100B in patients with cutaneous melanoma: a meta-analysis. Int J Cancer. 2008;123:2370-2376.
29. Schmidt H, Sorensen BS, Fode K, Nexo E, Von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res. 2005;15:409-416. (Pubitemid 41558951)
30. Buer J, Probst M, Franzke A, et al. Elevated serum levels of S100 and survival in metastatic malignant melanoma. Br J Cancer. 1997;75:1373-1376. (Pubitemid 27179831)
31. Bottoni U, Izzo P, Richetta A, et al. S100 serum level: a tumour marker for metastatic melanoma. Melanoma Res. 2003;13:427-429. (Pubitemid 36900707)
32. Hamberg AP, Korse CM, Bonfrer JM, De Gast GC. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res. 2003;13:45-49. (Pubitemid 36269813)
33. Krähn G, Kaskel P, Sander S, et al. S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res. 2001;21:1311-1316.
34. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol. 2002;23:39-44. (Pubitemid 34225020)
35. Blesch A, Bosserhoff AK, Apfel R, et al. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA. Cancer Res. 1994;54:5695-5701. (Pubitemid 24346269)
36. Bogdahn U, Apfel R, Hahn M, et al. Autocrine tumor cell growth-inhibiting activities from human malignant melanoma. Cancer Res. 1989;49:5358-5363. (Pubitemid 19240474)
37. Guba M, Bosserhoff AK, Steinbauer M, et al. Overexpression of melanoma inhibitory activity (MIA) enhances extravasation and metastasis of A-mel 3 melanoma cells in vivo. Br J Cancer. 2000;83:1216-1222.
38. Meral R, Duranyildiz D, Tas F, et al. Prognostic significance of melanoma inhibiting activity levels in malignant melanoma. Melanoma Res. 2001;11:627-632. (Pubitemid 33152354)
39. Bosserhoff AK, Buettner R. Expression, function and clinical relevance of MIA (melanoma inhibitory activity). Histol Histopathol. 2002;17:289-300. (Pubitemid 34116431)
40. Bosserhoff AK, Kaufmann M, Kaluza B, et al. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Cancer Res. 1997;57:3149-3153. (Pubitemid 27351728)
41. Stahlecker J, Gauger A, Bosserhoff A, Buttner R, Ring J, Hein R. MIA as a reliable tumor marker in the serum of patients with malignant melanoma. Anticancer Res. 2000;20:5041-5044. (Pubitemid 32319076)
42. Nevala WK, Vachon CM, Leontovich AA, Scott CG, Thompson MA, Markovic SN. Evidence of systemic Th2-driven chronic inflammation in patients with metastatic melanoma. Clin Cancer Res. 2009;15:1931-1939.
43. Mansfield AS, Holtan SG, Grotz TE, et al. Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. Mod Pathol. 2011;24(4):487-494.
44. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med. 1996;2:1096-1103. (Pubitemid 26338628)
45. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998;92:4150-4166. (Pubitemid 28544331)
46. Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer. 2009;100:1111-1119.
47. Ohm JE, Gabrilovich DI, Sempowski GD, et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003;101:4878-4886.
48. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001;19:577-583. (Pubitemid 32112873)
49. Osella-Abate S, Quaglino P, Savoia P, Leporati C, Comessatti A, Bernengo MG. VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course. Melanoma Res. 2002;12:325-334. (Pubitemid 34816437)
50. Pelletier F, Bermont L, Puzenat E, et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol. 2005;152:685-689. (Pubitemid 40571300)
51. Ugurel S, Utikal J, Becker JC. Tumor biomarkers in melanoma. Cancer Control. 2009;16(3):219-224.
52. Agrup P, Carstam R, Wittbjer A, Rorsman H, Rosengren E. Tyrosinase activity in serum from patients with malignant melanoma. Acta Derm Venereol. 1989;69:120-124. (Pubitemid 19057350)
53. Wimmer I, Meyer JC, Seifert B, Dummer R, Flace A, Burg G. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy. Cancer Res. 1997;57:5073-5076. (Pubitemid 27498122)
54. Hirai S, Kageshita T, Kimura T, et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res. 1997;7:58-62. (Pubitemid 27110283)
55. Stoitchkov K, Letellier S, Garnier JP, et al. Evaluation of the serum L-dopa/L-tyrosine ratio as a melanoma marker. Melanoma Res. 2003;13:587-593. (Pubitemid 38296896)
56. Vuoristo MS, Laine S, Huhtala H, et al. Serum adhesion molecules and interleukin-2 receptor as markers of tumour load and prognosis in advanced cutaneous melanoma. Eur J Cancer. 2001;37:1629-1634. (Pubitemid 32778608)
57. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res. 2005;11:5158-5166. (Pubitemid 41003701)
58. Yoshino Y, Kageshita T, Nakajima M, Funakubo M, Ihn H. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma. J Dermatol. 2008;35:206-214. (Pubitemid 351561711)
59. Mouawad R, Benhammouda A, Rixe O, et al. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res. 1996;2:1405-1409. (Pubitemid 26299441)
60. Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB. Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res. 1995;5:67-68.
61. Nemunaitis J, Fong T, Shabe P, Martineau D, Ando D. Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest. 2001;19:239-247. (Pubitemid 32374364)
62. Rebmann V, Ugurel S, Tilgen W, Reinhold U, Grosse-Wilde H. Soluble HLA-DR is a potent predictive indicator of disease progression in serum from early-stage melanoma patients. Int J Cancer. 2002;100:580-585. (Pubitemid 34816159)
63. Westhoff U, Fox C, Otto FJ. Soluble HLA class I antigens in plasma of patients with malignant melanoma. Anticancer Res. 1998;18:3789-3792. (Pubitemid 28564267)
64. Ugurel S, Bell N, Sucker A, Zimpfer A, Rittgen W, Schadendorf D. Tumor type M2 pyruvate kinase (TuM2-PK) as a novel plasma tumor marker in melanoma. Int J Cancer. 2005;117:825-830. (Pubitemid 41598835)
65. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol. 2005;125:526-531.
66. Hahn S, Ugurel S, Hanschmann KM, et al. Serological response to human endogenous retrovirus K in melanoma patients correlates with survival probability. AIDS Res Hum Retroviruses. 2008;24:717-723. (Pubitemid 351748779)
67. Hoon DS, Wang Y, Dale PS, et al. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J Clin Oncol. 1995;13:2109-2116.
68. Mocellin S, Del Fiore P, Guarnieri L, et al. Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma. Int J Cancer. 2004;111:741-745. (Pubitemid 39062897)
69. Mellado B, Del Carmen Vela M, Colomer D, et al. Tyrosinase mRNA in blood of patients with melanoma treated with adjuvant interferon. J Clin Oncol. 2002;20:4032-4039.
70. Palmieri G, Ascierto PA, Perrone F, et al. Prognostic value of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction. J Clin Oncol. 2003;21:767-773. (Pubitemid 46606433)
71. Nezos A, Lembessis P, Sourla A, Pissimissis N, Gogas H, Koutsilieris M. Molecular markers detecting circulating melanoma cells by reverse transcription polymerase chain reaction: methodological pitfalls and clinical relevance. Clin Chem Lab Med. 2009;47:1-11.
72. Szenajch J, Jasinski B, Synowiec A, et al. Prognostic value of multiple reverse transcription-PCR tyrosinase testing for circulating neoplastic cells in malignant melanoma. Clin Chem. 2003;49:1450-1457. (Pubitemid 37011732)
73. Mitropapas G, Nezos A, Halapas A, et al. Molecular detection of tyrosinase transcripts in peripheral blood from patients with malignant melanoma: correlation of PCR sensitivity threshold with clinical and pathologic disease characteristics. Clin Chem Lab Med. 2006;44:1403-1409. (Pubitemid 44967687)
74. De Vries TJ, Fourkour A, Punt CJ, et al. Reproducibility of detection of tyrosinase and MART-1 transcripts in the peripheral blood of melanoma patients: a quality control study using real-time quantitative RT-PCR. Br J Cancer. 1999;80:883-891. (Pubitemid 29209855)
75. Hoon DS, Bostick P, Kuo C, et al. Molecular markers in blood as surrogate prognostic indicators of melanoma recurrence. Cancer Res. 2000;60:2253-2257. (Pubitemid 30225191)
76. Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE. Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem. 2007;53:1206-1215. (Pubitemid 47020975)
77. Voit C, Kron M, Rademaker J, et al. Molecular staging in stage II and III melanoma patients and its effect on long-term survival. J Clin Oncol. 2005;23:1218-1227. (Pubitemid 46202279)
78. Curry BJ, Myers K, Hersey P. Polymerase chain reaction detection of melanoma cells in the circulation: relation to clinical stage, surgical treatment, and recurrence from melanoma. J Clin Oncol. 1998;16:1760-1769. (Pubitemid 28234720)
79. Osella-Abate S, Savoia P, Quaglino P, et al. Tyrosinase expression in the peripheral blood of stage III melanoma patients is associated with a poor prognosis: a clinical follow-up study of 110 patients. Br J Cancer. 2003;89:1457-1462. (Pubitemid 37386600)
80. Visus C, Andres R, Mayordomo JI, et al. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res. 2007;17:83-89. (Pubitemid 46673901)
81. Quaglino P, Savoia P, Fierro MT, Osella-Abate S, Bernengo MG. Clinical significance of sequential tyrosinase expression in the peripheral blood of disease-free melanoma patients: a review of literature data. Melanoma Res. 2004;14:S17-S19.
82. Callejo SA, Antecka E, Blanco PL, Edelstein C, Burnier MN Jr. Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma: a prospective longitudinal study. Eye (Lond). 2007;21:752-759. (Pubitemid 46909176)
83. Tsao H, Nadiminti U, Sober AJ, Bigby M. A meta-analysis of reverse transcriptase-polymerase chain reaction for tyrosinase mRNA as a marker for circulating tumor cells in cutaneous melanoma. Arch Dermatol. 2001;137:325-330. (Pubitemid 32240787)
84. Blake JA, Ziman MR. Pax3 transcripts in melanoblast development. Dev Growth Differ. 2005;47:627-635. (Pubitemid 43151678)
85. Vachtenheim J, Novotna H. Expression of genes for microphthalmia isoforms, Pax3 and MSG1, in human melanomas. Cell Mol Biol (Noisy-le-grand). 1999;45:1075-1082.
86. Schrader AJ, Probst-Kepper M, Grosse J, et al. Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cells. Melanoma Res. 2000;10:355-362.
87. Itakura E, Huang RR, Wen DR, Paul E, Wunsch PH, Cochran AJ. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi. Mod Pathol. 2008;21:326-333. (Pubitemid 351304287)
88. Arenberger P, Arenbergerova M, Gkalpakiotis S, Lippert J, Stribrna J, Kremen J. Multimarker real-time reverse transcription-PCR for quantitative detection of melanoma-associated antigens: a novel possible staging method. J Eur Acad Dermatol Venereol. 2008;22:56-64.
89. Matsuzaki Y, Hashimoto S, Fujita T, et al. Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE). J Immunother. 2005;28:10-19. (Pubitemid 40075933)
90. Theos AC, Truschel ST, Raposo G, Marks MS. The Silver locus product Pmel17/gp100/Silv/ME20: controversial in name and in function. Pigment Cell Res. 2005;18:322-336. (Pubitemid 41360808)
91. Du J, Miller AJ, Widlund HR, Horstmann MA, Ramaswamy S, Fisher DE. MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma. Am J Pathol. 2003;163:333-343. (Pubitemid 36759618)
92. Tsukamoto K, Ueda M, Hirata S, et al. gp100 mRNA is more sensitive than tyrosinase mRNA for RT-PCR amplification to detect circulating melanoma cells in peripheral blood of melanoma patients. J Dermatol Sci. 2000;23:126-131. (Pubitemid 30243160)
93. Keilholz U, Goldin-Lang P, Bechrakis NE, et al. Quantitative detection of circulating tumor cells in cutaneous and ocular melanoma and quality assessment by real-time reverse transcriptase-polymerase chain reaction. Clin Cancer Res. 2004;10:1605-1612. (Pubitemid 38435549)
94. Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature. 2005;433:764-769. (Pubitemid 40292987)
95. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature. 2005;436:117-122. (Pubitemid 40966196)
96. Koyanagi K, O'Day SJ, Gonzalez R, et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res. 2006;12:1137-1143. (Pubitemid 43342501)
97. Samija I, Lukac J, Maric-Brozic J, Kusic Z. Microphthalmia-associated transcription factor and tyrosinase as markers of melanoma cells in blood of patients with melanoma. Croat Med J. 2004;45:142-148. (Pubitemid 38724576)
98. Ugurel S, Houben R, Schrama D, et al. Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response. Clin Cancer Res. 2007;13:6344-6350. (Pubitemid 350075023)
99. Sarantou T, Chi DD, Garrison DA, et al. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res. 1997;57:1371-1376. (Pubitemid 27152564)
100. Enk CD, Lotem M, Gimon Z, Hochberg M. Molecular detection of MART-1, tyrosinase and MIA in peripheral blood, lymph nodes and metastatic sites of stage III/IV melanoma patients. Melanoma Res. 2004;14:361-365. (Pubitemid 39431231)
101. Reynolds SR, Albrecht J, Shapiro RL, et al. Changes in the presence of multiple markers of circulating melanoma cells correlate with clinical outcome in patients with melanoma. Clin Cancer Res. 2003;9:1497-1502. (Pubitemid 36418407)
102. Koyanagi K, O'Day SJ, Gonzalez R, et al. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial. J Clin Oncol. 2005;23:8057-8064. (Pubitemid 46657408)
103. Mellado B, Gutierrez L, Castel T, et al. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients. Clin Cancer Res. 1999;5:1843-1848. (Pubitemid 29334467)
104. Albelda SM, Oliver PD, Romer LH, Buck CA. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol. 1990;110:1227-1237.
105. Kulik J, Nowecki ZI, Rutkowski P, et al. Detection of circulating melanoma cells in peripheral blood by a two-marker RT-PCR assay. Melanoma Res. 2001;11:65-73. (Pubitemid 32158187)
106. Koyanagi K, Kuo C, Nakagawa T, et al. Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem. 2005;51:981-988. (Pubitemid 40740878)
107. Sridhar SS, Hedley D, Siu LL. Raf kinase as a target for anticancer therapeutics. Mol Cancer Ther. 2005;4:677-685. (Pubitemid 40601850)
108. Poust J. Targeting metastatic melanoma. Am J Health Syst Pharm. 2008;65:S9-S15.
109. Dhomen N, Marais R. BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. 2009;23(3):529-545, ix.
110. Dong J, Phelps RG, Qiao R, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003;63:3883-3885. (Pubitemid 36917898)
111. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res. 2003;9:6483-6488. (Pubitemid 38031837)
112. Houben R, Becker JC, Kappel A, et al. Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog. 2004;3(1):6.
113. Shinozaki M, O'Day SJ, Kitago M, et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res. 2007;13:2068-2074. (Pubitemid 46649874)
114. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci. 2010;101(10):2087-2092.
115. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008;141:672-675. (Pubitemid 351667616)
116. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105:10513-10518.
117. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110:13-21. (Pubitemid 351853251)
118. Zhu W, Qin W, Atasoy U, Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009;2:89.
119. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102(7):1174-1179.
120. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009;2(9):807-813.
121. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375-1381.
122. Mian S, Ugurel S, Parkinson E, et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol. 2005;23:5088-5093. (Pubitemid 46224016)